rosiglitazone has been researched along with dehydroepiandrosterone in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Apostolova, G; Balazs, Z; Kostadinova, RM; Odermatt, A; Schweizer, RA | 1 |
| Morin-Papunen, LC; Rautio, K; Ruokonen, A; Tapanainen, JS | 1 |
| Bahtiyar, G; Sacerdote, AS; Weiss, K | 1 |
| Balvers, MG; Dwarkasing, J; Lute, C; Meijerink, J; Plastina, P; Poland, M; van Norren, K; Witkamp, RF | 1 |
| Chen, A; Jin, R; Lu, J; Ren, Y; Xuan, F; Ye, Y; Zhou, W | 1 |
1 trial(s) available for rosiglitazone and dehydroepiandrosterone
| Article | Year |
|---|---|
Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Area Under Curve; Dehydroepiandrosterone; Double-Blind Method; Female; Glucose Tolerance Test; Humans; Overweight; Placebos; Polycystic Ovary Syndrome; Rosiglitazone; Sex Hormone-Binding Globulin; Thiazolidinediones | 2006 |
5 other study(ies) available for rosiglitazone and dehydroepiandrosterone
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Dehydroepiandrosterone inhibits the amplification of glucocorticoid action in adipose tissue.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; 3T3-L1 Cells; Adipose Tissue; Animals; Dehydroepiandrosterone; Dose-Response Relationship, Drug; Gene Expression Regulation; Glucocorticoids; Liver; Male; Mice; Mice, Inbred C57BL; Rosiglitazone; Thiazolidinediones | 2005 |
Novel endocrine disrupter effects of classic and atypical antipsychotic agents and divalproex: induction of adrenal hyperandrogenism, reversible with metformin or rosiglitazone.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adrenal Glands; Adult; Aged; Antipsychotic Agents; Cortodoxone; Dehydroepiandrosterone; Endocrine Disruptors; Estradiol; Estrone; Female; Follicle Stimulating Hormone; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin Resistance; Luteinizing Hormone; Male; Metformin; Middle Aged; Radioimmunoassay; Rosiglitazone; Testosterone; Thiazolidinediones; Valproic Acid | 2007 |
Inhibition of COX-2-mediated eicosanoid production plays a major role in the anti-inflammatory effects of the endocannabinoid N-docosahexaenoylethanolamine (DHEA) in macrophages.
Topics: Anilides; Animals; Arachidonic Acids; Camphanes; Cell Line; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dehydroepiandrosterone; Dinoprostone; Endocannabinoids; Indenes; Interferon-beta; Lipopolysaccharides; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myeloid Differentiation Factor 88; NF-kappa B; Nitric Oxide; Piperidines; PPAR gamma; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant; Rosiglitazone; Thiazolidinediones; Toll-Like Receptor 3; Toll-Like Receptor 4 | 2015 |
The ameliorating effects of Guizhi Fuling Wan combined with rosiglitazone in a rat ovarian model of polycystic ovary syndrome by the PI3K/AKT/NF-κB and Nrf2/HO-1 pathways.
Topics: Animals; Dehydroepiandrosterone; Female; Humans; NF-E2-Related Factor 2; NF-kappa B; Phosphatidylinositol 3-Kinases; Polycystic Ovary Syndrome; Proto-Oncogene Proteins c-akt; Rats; Rosiglitazone | 2023 |